Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit
Rhea-AI Summary
Lipella Pharmaceuticals (Nasdaq: LIPO), a clinical-stage biotechnology company, has announced its participation in the 2024 Maxim Healthcare Virtual Summit. CEO Jonathan Kaufman, PhD, will be presenting at the event on Thursday, October 17th, 2024, at 10:30am.
The summit is scheduled to take place from October 15-17, 2024. Interested parties can access the webcast of Lipella's presentation at https://m-vest.com/events/healthcare-10152024. Additionally, Dr. Kaufman will be available for one-on-one meetings with registered investors attending the conference.
Lipella Pharmaceuticals focuses on developing treatments for serious diseases with significant unmet needs, positioning itself as a key player in the biotechnology sector.
Positive
- None.
Negative
- None.
News Market Reaction – LIPO
In the trading session that priced this news, LIPO gained 0.12%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PITTSBURGH, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on addressing serious diseases with significant unmet needs, today announced that CEO Jonathan Kaufman, PhD will be presenting at the 2024 Maxim Healthcare Virtual Summit that is being held on October 15 -17, 2024.
Event: Lipella Presentation - 2024 Maxim Healthcare Virtual Summit
Date: Thursday, October 17th, 2024
Time: 10:30am
Webcast: https://m-vest.com/events/healthcare-10152024
Jonathan Kaufman will be available for one-on-one meetings with registered investors of the conference.
About Lipella Pharmaceuticals
Lipella is a clinical-stage biotechnology company focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Additionally, Lipella maintains a therapeutic focus on diseases with significant, unaddressed morbidity and mortality where no approved drug therapy currently exists. Lipella completed its initial public offering in December 2022. For more information, please visit www.lipella.com or LinkedIn
CONTACT
Jeff Ramson
PCG Advisory
jramson@pcgadvisory.com
646-863-6893
